Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Complement System01:27

Complement System

8.1K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.6K
Hybridoma Technology01:31

Hybridoma Technology

16.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026
Same author

A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant.

Transplantation and cellular therapy·2026
Same author

Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel.

Blood cell therapy·2026
Same author

CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV Trial.

Blood·2026
Same author

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Blood advances·2026
Same author

Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.

Case reports in oncology·2026

Related Experiment Video

Updated: Dec 10, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Joseph Tuscano1,2, Christina Poh1,3, Aaron Rosenberg1

  • 1University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Journal of Hematology
|August 29, 2020
PubMed
Summary

Ofatumumab combined with fresh frozen plasma showed high response rates in chronic lymphocytic leukemia. Complement replacement may enhance monoclonal antibody efficacy with minimal toxicity.

Keywords:
Chronic lymphocytic leukemiaFresh frozen plasmaOfatumumab

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.1K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Monoclonal antibodies often rely on complement-dependent cytotoxicity.
  • The impact of complement depletion and replacement on treatment outcomes is not fully understood.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ofatumumab with fresh frozen plasma (FFP) in relapsed/refractory chronic lymphocytic leukemia (CLL).
  • To assess the effects of FFP as a complement replacement strategy during ofatumumab treatment.

Main Methods:

  • A phase 2 clinical trial was conducted on patients with relapsed/refractory CLL.
  • Patients received ofatumumab with FFP for complement replacement.
  • Objective response rate was the primary endpoint, with correlative analyses of complement levels (C3, C4) and activity (CH50).

Main Results:

  • An overall response rate of 83% was observed, including 17% complete responses.
  • Complement activity decreased in 67% of patients post-treatment, but depletion magnitude did not correlate with response.
  • The combination therapy was well-tolerated with minimal adverse events.

Conclusions:

  • Ofatumumab and FFP combination demonstrated significant activity and tolerability in high-risk CLL.
  • Complement replacement warrants further investigation as a strategy to improve monoclonal antibody therapy efficacy.